Cathie Wood Uro Gen Pharma Ltd. Transaction History

Ark Investment Management LLC

$9.28 Billion
Q1 2025

A detailed history of Cathie Wood (Ark Investment Management LLC) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Ark Investment Management LLC holds 185,790 shares of URGN stock, worth $1.54 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

185,790

Previous 140,148 32.57%

Holding current value

$1.54 Million

Previous $1.49 Million 37.67%

% of portfolio

0.02%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	BUY	$9.27 - $12.13 $423,101 - $553,637	45,642 Added 32.57%	185,790 $2.05 Million
Q4 2024 Feb 04, 2025	BUY	$10.52 - $13.11 $194,767 - $242,718	18,514 Added 15.22%	140,148 $1.49 Million
Q3 2024 Oct 31, 2024	SELL	$12.7 - $17.92 $382,866 - $540,234	-30,147 Reduced 19.86%	121,634 $1.54 Million
Q2 2024 Jul 26, 2024	BUY	$12.72 - $19.2 $69,349 - $104,678	5,452 Added 3.73%	151,781 $2.55 Million
Q1 2024 Apr 18, 2024	SELL	$13.81 - $19.33 $209,856 - $293,738	-15,196 Reduced 9.41%	146,329 $2.19 Million
Q4 2023 Jan 17, 2024	SELL	$10.87 - $15.93 $584,229 - $856,189	-53,747 Reduced 24.97%	161,525 $2.42 Million
Q3 2023 Oct 18, 2023	BUY	$8.84 - $22.64 $118,049 - $302,334	13,354 Added 6.61%	215,272 $3.02 Million
Q2 2023 Jul 10, 2023	SELL	$8.75 - $14.29 $602,245 - $983,552	-68,828 Reduced 25.42%	201,918 $2.09 Million
Q1 2023 Apr 17, 2023	BUY	$7.99 - $11.02 $589,725 - $813,364	73,808 Added 37.48%	270,746 $2.5 Million
Q4 2022 Jan 24, 2023	SELL	$7.55 - $11.96 $639,960 - $1.01 Million	-84,763 Reduced 30.09%	196,938 $0
Q3 2022 Oct 17, 2022	SELL	$7.21 - $9.41 $147,249 - $192,180	-20,423 Reduced 6.76%	281,701 $2.34 Million
Q2 2022 Jul 11, 2022	SELL	$5.12 - $8.74 $160,501 - $273,981	-31,348 Reduced 9.4%	302,124 $1.61 Million
Q1 2022 Apr 19, 2022	BUY	$5.92 - $9.73 $870,115 - $1.43 Million	146,979 Added 78.81%	333,472 $2.91 Million
Q4 2021 Jan 28, 2022	SELL	$9.03 - $19.13 $520,778 - $1.1 Million	-57,672 Reduced 23.62%	186,493 $1.77 Million
Q3 2021 Nov 12, 2021	SELL	$14.31 - $18.39 $1.03 Million - $1.33 Million	-72,083 Reduced 22.79%	244,165 $4.11 Million
Q2 2021 Aug 05, 2021	BUY	$15.2 - $20.94 $370,545 - $510,475	24,378 Added 8.35%	316,248 $4.83 Million
Q1 2021 May 13, 2021	BUY	$17.99 - $26.96 $3.92 Million - $5.88 Million	218,101 Added 295.65%	291,870 $5.69 Million
Q4 2020 Feb 12, 2021	BUY	$17.54 - $25.43 $693,829 - $1.01 Million	39,557 Added 115.62%	73,769 $1.33 Million
Q3 2020 Oct 30, 2020	SELL	$18.81 - $26.42 $244,454 - $343,354	-12,996 Reduced 27.53%	34,212 $660,000
Q2 2020 Aug 11, 2020	BUY	$16.5 - $29.7 $501,385 - $902,493	30,387 Added 180.65%	47,208 $1.23 Million
Q1 2020 May 14, 2020	BUY	$13.68 - $34.6 $10,889 - $27,541	796 Added 4.97%	16,821 $300,000
Q4 2019 Jan 31, 2020	BUY	$21.11 - $34.86 $37,786 - $62,399	1,790 Added 12.57%	16,025 $535,000
Q3 2019 Nov 12, 2019	BUY	$23.83 - $36.44 $16,823 - $25,726	706 Added 5.22%	14,235 $339,000
Q2 2019 Jul 30, 2019	BUY	$32.75 - $40.35 $148,095 - $182,462	4,522 Added 50.21%	13,529 $486,000
Q1 2019 May 13, 2019	SELL	$35.47 - $54.55 $81,261 - $124,974	-2,291 Reduced 20.28%	9,007 $333,000
Q4 2018 Feb 01, 2019	BUY	$38.35 - $50.39 $1,534 - $2,015	40 Added 0.36%	11,298 $486,000
Q3 2018 Nov 07, 2018	BUY	$41.65 - $51.7 $75,803 - $94,094	1,820 Added 19.28%	11,258 $532,000
Q2 2018 Aug 07, 2018	SELL	$48.35 - $65.33 $196,494 - $265,501	-4,064 Reduced 30.1%	9,438 $470,000
Q1 2018 May 14, 2018	BUY	$38.64 - $57.54 $162,983 - $242,703	4,218 Added 45.43%	13,502 $671,000
Q4 2017 Feb 12, 2018	BUY	$27.28 - $43.26 $253,267 - $401,625	9,284	9,284 $345,000

Others Institutions Holding URGN

# of Institutions

142

Shares Held

41.6M

Call Options Held

91.4K

Put Options Held

42.1K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $189M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track Cathie Wood's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.

Account